A drug that could extend the lifespan of dogs is being developed by scientists
We (mankind) don’t often get to say this, but humanity has gotten some good news, as reports indicate scientists are developing a medicine that could help dogs live longer.
The drug, LOY-002, is being developed by a biotech company called Loyal and is a prescription daily pill designed to extend the healthy lifespan of senior dogs.
According to Loyal, LOY-002 is intended for dogs 10 and older that weigh at least 14 pounds. It targets age-related metabolic dysfunction using “caloric restriction mimicry,” with the idea being that copying the effects of eating less could slow aging.
Scientists are developing a life-extending drug for dogs that would be the first-ever FDA-approved lifespan extension drug in any species
LOY-002 has cleared two of the three major FDA technical sections needed for conditional approval. Should it get over the line, it would become the first FDA-approved lifespan extension drug in any species.
“Since founding Loyal six years ago, my goal has always been to get the first drug FDA approved for lifespan extension,” CEO Celine Halioua said.
The FDA accepted the drug’s reasonable expectation of effectiveness section in early 2025, then signed off on its target animal safety section in January 2026. The safety package included a standard study at one, three, and five times the normal dose, which reportedly turned up no clinically significant adverse events, plus field data from more than 400 dogs.
That field data comes from the STAY study, which enrolled about 1,300 pets at 70 veterinary clinics and is billed as the largest clinical trial in veterinary history. Efficacy results from that trial aren’t out yet, so how many extra years the pill could actually add remains unproven.
Despite the positive developments, the drug is likely still a ways from hitting the market. Loyal expects the FDA to review its manufacturing section in 2027, which would then allow the company to seek expanded conditional approval.